WASHINGTON, September 30, 2021 / PRNewswire / – A new Ipsos / PhRMA poll shows that initial support for medicare “negotiation” evaporates once Americans are given arguments around the debate. Public opinion drops to 51 percentage points, overall, when Americans see arguments for both ânegotiatingâ drug prices.
The survey was conducted among 5,029 American adults using KnowledgePanelÂ®, Ipsos’ gold standard, representative of the American public, based on probability. The margin of sampling error is plus or minus 1.6 percentage points at the 95% confidence level, for results based on the entire sample of adults.
âAs voters learn about the extreme policies discussed in Washington, they send a clear message to policy makers: don’t sacrifice access and innovation, âsaid Stephen J. Ubl, President and CEO, PhRMA. âAmericans don’t want Congress to fundamentally upend Medicare and interfere with decisions that are best left to patients and their doctors. Instead, the public wants lawmakers to attack the real ones. affordability challenges people face in pharmacy, which is why our industry remains committed to fighting for solutions that reduce out-of-pocket drug costs, while protecting access to life-saving treatments and future innovation. “
Voters don’t want to sacrifice access and innovation
This survey and other recent non-partisan polls show that support for Medicare “negotiation” declines dramatically once people learn more about the policy proposal. Specifically:
- Only 15% support when told it could limit people’s access to new prescription drugs
- Only 15% of them agree when told that taxing drugs up to 95% for non-compliance could make money for research for new drugs and treatments.
- Only 16% of them claim that this could lead to a decrease in research and development of new drugs.
Support falls especially when Americans learn that drug price negotiations could limit people’s access to new prescription drugs. Notably, there is a significant shift in support among key demographics:
- Support for Democrats drops 61 points (from 77% to 16%) after learning that politics could limit access.
- Support for seniors drops by 58 points (from 70% to 12%)
- Hispanic support decreases by 51 points (from 67% to 16%).
Americans want policymakers to focus on health insurance costs and coverage
Respondents identified health insurance costs and coverage as the most significant problem facing the U.S. healthcare system and prioritized solutions that would reduce their out-of-pocket expenses.
- After insurance costs (44%) and the pandemic (37%), bureaucracy, inefficiency and waste in the system (30%) and out-of-pocket expenses (28%) are cited as the main concerns. health care. The cost of prescription drugs is the fifth most important health problem for Americans, with 26% of them believing it to be a major problem in the health care system.
- When given a choice, 77% say Congress should focus more on reducing the overall costs of health care coverage such as premiums, deductibles and co-payments rather than focusing more on health care coverage. reduction in prescription drug costs (22%).
- Eighty-six percent agree that politicians have lost touch with the public’s health care needs.
Voters want pragmatic political solutions – not government pricing
Investigation shows that instead of fixing the price of prescription drugs, Americans broadly support policy proposals that allow government oversight and address their most pressing concerns about health insurance coverage – uncovered costs through insurance.
- 72% believe the federal government should provide oversight and incentives to healthcare providers, prescription drug companies and health insurers to encourage more competition to drive down prices in the healthcare system in relation to pricing health services and prescription drugs and determining which services and drugs are covered by private health plans (27%).
About three-quarters of Americans’ support demand that health insurers pass on the discounts they receive from drug companies on drugs to patients at the pharmacy (75%), further incentivizing health insurers to maintain the prices of health plans. low health for people (74%) and reduce unnecessary expenses by eliminating unnecessary procedures, duplicate testing and administrative overhead (73%).
The survey strengthens support for PhRMA’s program and patient-centered solutions that would make the healthcare system more affordable.
For more details on the Ipsos / PhRMA survey click here.
Pharmaceutical Research and Manufacturers of America (PhRMA) represents the nation’s leading innovative biopharmaceutical research companies, dedicated to the discovery and development of drugs that allow patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than 1000 billion dollars looking for new treatments and cures, including $ 91.1 billion in 2020 alone.
Connect with PhRMA
For more information on how innovative medicines save lives, please visit:
SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)